Citi lowered the firm’s price target on Crinetics (CRNX) to $68 from $74 and keeps a Buy rating on the shares. The company reported Q4 results and provided an update on the status of its portfolio, the analyst tells investors in a research note. The firm says Crinetics has made strong clinical progress across its pipeline, setting up 2025 for the company’s first commercial launch to-date.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Pharmaceuticals: Promising Future with Paltusotine Launch and Robust Pipeline Development
- Crinetics Pharmaceuticals: Positioned for Growth with Promising Drug Pipeline and Strong Financials
- Crinetics Pharmaceuticals: Financial Results and Future Plans
- Crinetics reports Q4 EPS (88c), consensus (89c)
- Crinetics Pharmaceuticals Appoints New Chief Financial Officer